Ticker

VAREX IMAGING (VREX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The average of price targets set by Wall Street analysts indicates a potential upside of 57.6% in VAREX IMAGING (VREX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

JPMorgan Chase and Co. grew its stake in shares of Varex Imaging (NASDAQ: VREX) by 381.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 284,227 shares of the company's stock after buying an additional 225,238 shares during the quarter. JPMorgan

High Tide (NASDAQ: HITI - Get Free Report) and Varex Imaging (NASDAQ: VREX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation. Insider and Institutional Ownership 4.5% of High

SALT LAKE CITY--(BUSINESS WIRE)--Varex Imaging Corporation (Nasdaq: VREX) today announced it has entered into a Credit and Guaranty Agreement (the “Credit Agreement”), dated as of March 13, 2026, which includes a secured term loan facility in aggregate principal amount of $350 million, a secured revolving credit facility in aggregate principal amount of $100 million and a secured delayed draw term loan facility in…